Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006161 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006074 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1005294 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006397 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006453 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1007393 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL330805 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL910572 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1007075 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 | |
| SCHEMBL1006646 | 1.00 | LMNA (0.44) | LMNATHRBCA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397405-A1 | CARBON DIOXIDE CAPTURING AGENT, METAL-ORGANIC FRAMEWORK, AND COMPOUND | ENEOS Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| US-12034122-B2 | Electrolytic solution for lithium-ion secondary battery and lithium-ion secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| CN-115003751-B | Polymer composition, molded body, and optical member | 住友化学株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-112074983-B | Electrolyte for lithium ion secondary battery and lithium ion secondary battery | 株式会社村田制作所 | 2024-06-04 | — | — | CN | disclosed |
| CN-117897225-A | Carbon dioxide scavenger, metal-organic structure, and compound | 引能仕株式会社 | 2024-04-16 | — | — | CN | disclosed |
| US-20240122065-A1 | METAL PATTERNING MATERIAL, AMINE COMPOUND, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | TOSOH CORPORATION (JP) | 2024-04-11 | — | — | US | disclosed |
| US-20230405155-A1 | NANOPARTICLE, PHOTOACOUSTIC CONTRAST AGENT, PHOTODYNAMIC THERAPY DRUG, AND PHOTOTHERMAL THERAPY DRUG | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-12-21 | — | — | US | disclosed |
| CN-116761861-A | polarizing plate | 住友化学株式会社 | 2023-09-15 | — | — | CN | disclosed |
| EP-4241846-A1 | NANOPARTICLES, PHOTOACOUSTIC CONTRAST AGENT, PHOTODYNAMIC THERAPEUTIC AGENT, AND PHOTOTHERMAL THERAPEUTIC AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-09-13 | — | — | EP | disclosed |
| EP-4198163-A1 | METAL PATTERNING MATERIAL, AMINE COMPOUND, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | Tosoh Corporation (JP) | 2023-06-21 | — | — | EP | disclosed |
| US-6265135-B1 | ARYL SULFONIUM OR IODONIUM COMPOUND WHICH GENERATES BENZENE-, NAPHTHALENE- OR ANTHRACENESULFONIC ACID WHICH IS SUBSTITUTED BY AT LEAST ONE FLUORINE ATOM AND/OR AT LEAST ONE GROUP CONTAINING A FLUORINE ATOM. | FUJI PHOTO FILM CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-1117004-A2 | Electron beam or x-ray negative-working resist composition | FUJI PHOTO FILM CO., LTD. (JP) | 2001-07-18 | — | — | EP | disclosed |
| EP-1117002-A1 | Negative-working resist composition | FUJI PHOTO FILM CO., LTD. (JP) | 2001-07-18 | — | — | EP | disclosed |
| EP-1109066-A1 | Chemical amplification type negative-working resist composition for electron beams or x-rays | FUJI PHOTO FILM CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-6238752-B1 | MODIFIED DIAMINE | CHISSO CORPORATION (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-1076261-A1 | Negative resist composition | FUJI PHOTO FILM CO., LTD. (JP) | 2001-02-14 | — | — | EP | disclosed |
| EP-1020442-A1 | NOVEL DIAMINO COMPOUNDS, POLYAMIC ACID, POLYIMIDE, LIQUID-CRYSTAL ALIGNMENT FILM MADE FROM FILM OF THE POLYIMIDE, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE ALIGNMENT FILM | Chisso Corporation (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-6090909-A | Uv-ray-dimerized high molecular compound, liquid crystal aligning film using above high molecular compound and liquid crystal display element using above aligning film | CHISSO CORPORATION (JP) | 2000-07-18 | — | — | US | disclosed |
| US-5248339-A | Polyfluoropolyphazenes | EASTMAN KODAK COMPANY (US) | 1993-09-28 | — | — | US | disclosed |
| US-3938999-A | SURFACE ACTIVE ADDITION COPOLYMER | FUJI PHOTO FILM CO., LTD. (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230405155-A1 | NANOPARTICLE, PHOTOACOUSTIC CONTRAST AGENT, PHOTODYNAMIC THERAPY DRUG, AND PHOTOTHERMAL THERAPY DRUG | CRY2, RB1, NR2E3 | LMNA 3317/4885THRB 720/4885CA2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.